As part of the CURE® Educated Patient® Prostate Cancer Summit, an expert discussed the role genetic testing plays in ...

Itovebi is part of a push by Roche to make new inroads in breast cancer. Elsewhere, Turnstone is trimming preclinical research and Gritstone bio is working on a bankruptcy deal.

In the trial, a TALZENNA plus XTANDI combination regimen offered overall survival (OS) improvement in metastatic ...

Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...

Pfizer's drug combination improves survival in prostate cancer patients. Starboard Value pressures Pfizer over board conduct.

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of ...

On Thursday, Starboard Value LP, a significant shareholder of Pfizer Inc. (NYSE:PFE), issued a letter to the company’s Board ...

Pfizer Inc.’s stock dipped 2.5% Thursday after two of its former executives said they would not support an effort by activist ...

Company also reports positive data from trial of combination treatment for a form of prostate cancer Pfizer Inc.'s stock dipped 2.5% Thursday after two of its former executives said they would not ...

Pfizer’s Talzenna-Xtandi combination has marked a major step forward in treating advanced prostate cancer, improving patient ...

(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the ...